REG - Northern Trust Corp AbbVie Inc. - Form 8.3 - Allergan Plc

AbbvieAnnouncement

11/05/2020 14:45

RNS Number : 5211M
  
Northern Trust Corporation
  
11 May 2020
  
 

Ap19
 
 
FORM 8.3
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
 
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
 
1.       KEY INFORMATION
 



Name of person dealing (Note 1)


 Northern Trust Corporation




Company dealt in


 Allergan PLC




Class of relevant security to which the dealings being disclosed relate (Note 2)


 Common Stock USD 0.0033




Date of dealing


 8th May 2020
 



 
2.         INTERESTS AND SHORT POSITIONS
 
(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)







Long


Short








Number






(%)


Number






(%)




(1) Relevant securities


 3,723,324   1.14% 








(2) Derivatives (other than options)












(3) Options and agreements to purchase/sell












Total


 3,723,324   1.14% 
















 
Note: The difference in holdings from yesterday and today not explained by transactions, can be explained by stock transfers of 5,590 securities into the relevant accounts and 12 securities out of the relevant accounts.
 
(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)



Class of relevant security:


Long


Short








Number






(%)


Number






(%)




(1) Relevant securities












 
(2) Derivatives (other than options)












 
(3) Options and agreements to purchase/sell












Total




















 
Ap20
 
 
1.       DEALINGS (Note 4)
 
(a)      Purchases and sales
 
 



 
Purchase/sale


 
Number of relevant securities


 
Price per unit ($)




BUY


4


192.075




BUY


5


193.019




BUY


1


191.99




BUY


1


191.99




BUY


1


192.075




SELL


16


193.02




BUY


2


191.99




SELL


8598


193.02




BUY


1


192.075




BUY


1


191.99




BUY


6


193.02




BUY


3


192.075




BUY


1


191.99




BUY


20


191.99




BUY


7


192.075




SELL


3


191.98




SELL


4


191.98




BUY


5


191.99




BUY


2


192.075




BUY


3


192.56




SELL


23


191.92




SELL


2025


193.02




BUY


2


192.075




BUY


3


193.02




BUY


1


191.99




BUY


6


192.075




BUY


24


192.075




BUY


2


191.99




SELL


10


191.98




BUY


6


192.075




BUY


1


191.99




BUY


3


192.075




BUY


5


191.99




BUY


4


192.075




BUY


2


192.075




BUY


5


192.075




SELL


24


191.92




BUY


4


191.99




BUY


25


192.075




BUY


5


191.99




BUY


21


191.99




SELL


2


191.98




BUY


10


193.02




BUY


1


192.075




BUY


1


192.075




BUY


1


191.99




BUY


1


192.075




BUY


2


192.075




BUY


8


193.02




SELL


1111


193.02




BUY


4


191.99




BUY


560


192.09




BUY


13


192.63




SELL


8


193.02




BUY


2


191.99




BUY


5


191.99




SELL


5400


193.02




SELL


48


191.89



 
(b)      Derivatives transactions (other than options transactions)
 



Product name,
e.g. CFD


Nature of transaction
(Note 6)


Number of relevant securities
(Note 7)


Price per unit
(Note 5)





















 
 
(c)      Options transactions in respect of existing relevant securities
 
 
(i)       Writing, selling, purchasing or varying
 



Product name,
e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc.


Expiry date


Option money paid/received per unit (Note 5)

































 
 
(ii)      Exercising
 



Product name,
e.g. call option


Number of securities


Exercise price per unit (Note 5)

















 
 
(d)      Other dealings (including transactions in respect of new securities) (Note 4)
 



Nature of transaction
(Note 8)


Details


Price per unit
(if applicable) (Note 5)

















Ap21
 
 
 
 
 
 
 
 
 
 
2.       OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 
 
 
 
 
 
 
 
 
 
Is a Supplemental Form 8 attached? (Note 9)                                            NO
 



Date of disclosure


11th May 2020




Contact name


 Frances McIlrath 




Telephone number


 2079823386




If a connected EFM, name of offeree/offeror with which connected


 
 




If a connected EFM, state nature of connection (Note 10)







 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISESFDFEFESSELI